Black-box on Xolair prompts lesson for managing medications
Yesterday the wording was released for the black box or warning label on the asthma drug Xolair by Genentech Inc. The medication, generically known as omalizumab, is given by injection and was developed for individuals ages 12 and above who have moderate to severe allergic asthma and have not responded to inhaled steroids. The FDA... Read more









